Therapeutic potential of ketotifen in irritable bowel syndrome (IBS) may involve changes in mast cells at sites beyond the rectum

Gut

Volumn 60, Issue 3, 2011, Pages 423-

  O'Sullivan, Maria ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE; KETOTIFEN; TRYPTASE;

CELL COUNT; DRUG EFFECT; HUMAN; IRRITABLE COLON; LETTER; MAST CELL; PATHOGENESIS; PRIORITY JOURNAL; RECTUM;

HISTAMINE H1 ANTAGONISTS; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; KETOTIFEN; MAST CELLS;

EID: 79851510588     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.225078     Document Type: Letter

References (4)

1. Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010;59:1213-21.
2. Barbara G, Stanghellini V, De Giorgio R, et al. Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 2006;18:6-17.
3. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163-73.
4. O'Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000;12:449-57.